Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 14, 2023; 29(18): 2875-2887
Published online May 14, 2023. doi: 10.3748/wjg.v29.i18.2875
Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt
Liang Yin, Sen-Lin Chu, Wei-Fu Lv, Chun-Ze Zhou, Kai-Cai Liu, Yi-Jiang Zhu, Wen-Yue Zhang, Cui-Xia Wang, Yong-Hui Zhang, Dong Lu, De-Lei Cheng
Liang Yin, Sen-Lin Chu, Wei-Fu Lv, Chun-Ze Zhou, Yi-Jiang Zhu, Wen-Yue Zhang, Cui-Xia Wang, Yong-Hui Zhang, Dong Lu, De-Lei Cheng, Department of Interventional Radiology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230022, Anhui Province, China
Kai-Cai Liu, Infection Hospital, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230000, Anhui Province, China
Author contributions: Yin L and Chu SL designed the research, analyzed the data, and wrote the initial draft of the manuscript; Zhou CZ, Liu KC, Zhu YJ and Lu D collected the data, analyzed the data, and designed the study; Zhang WY, Wang CX and Zhang YH performed the research and collected the data; Lv WF and Cheng DL contributed to the central idea, designed the study, and wrote the manuscript.
Supported by Natural Science Foundation of Anhui Province, No. 2108085MH301; and The Key Project of University Research Found of Anhui Province Education Department, No. 2022AH040189.
Institutional review board statement: The retrospective study protocol was approved by the institutional review board of The First Affiliated Hospital of University of Science and Technology of China, No. 2022-RE-461.
Informed consent statement: Informed consent for the study was waived due to the retrospective nature of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated and analyzed in the study are available from the corresponding author on reasonable request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: De-Lei Cheng, MD, Department of Interventional Radiology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei 230022, Anhui Province, China. 39055004@qq.com
Received: January 29, 2023
Peer-review started: January 29, 2023
First decision: February 22, 2023
Revised: March 8, 2023
Accepted: April 17, 2023
Article in press: April 17, 2023
Published online: May 14, 2023
Core Tip

Core Tip: Few studies have investigated the relationship among sarcopenia, myosteatosis, and overt hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS). The present study revealed that the cumulative incidence of overt HE was the highest in patients with concomitant sarcopenia and myosteatosis, followed by patients with myosteatosis or sarcopenia, and the lowest incidence was found in patients without myosteatosis and sarcopenia. Sarcopenia and myosteatosis were the independent risk factors for overt HE and mortality in patients following TIPS. Therefore, identifying strategies for improving muscle mass (sarcopenia) and muscle fatty infiltration (myosteatosis) may help to reduce the incidence of HE after TIPS.